TY - JOUR
T1 - ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial
T2 - A multicenter fully nurse-coordinated intensive intervention program
AU - Paoli, Giorgia
AU - Notarangelo, Maria Francesca
AU - Mattioli, Maria
AU - La Sala, Rachele
AU - Foà, Chiara
AU - Solinas, Emilia
AU - Fusco, Sara
AU - Fava, Cristian
AU - Caminiti, Caterina
AU - Artioli, Giovanna
AU - Pelà, Giovanna
AU - Dall'Aglio, Elisabetta
AU - Manari, Antonio
AU - Tondi, Stefano
AU - Rizzo, Antonio
AU - Trapolin, Gaia
AU - Patrizi, Giampiero
AU - Cappelli, Stefano
AU - Villani, Giovanni Quinto
AU - Piepoli, Massimo
AU - Zobbi, Gianni
AU - Nicosia, Elisa
AU - Ardissino, Diego
PY - 2018/9/1
Y1 - 2018/9/1
N2 - The main objective of cardiovascular disease prevention is to reduce morbidity and mortality by promoting a healthy lifestyle, reducing risk factors, and improving adherence to medications. Secondary prevention after an acute coronary syndrome has proved to be effective in reducing new cardiovascular events, but its limited use in everyday clinical practice suggests that there is considerable room for improvement. The short-term results of evidence-based studies of nurse-coordinated secondary prevention programs have been positive, but there is a lack of long-term outcome data. The Alliance for the Secondary Prevention of Cardiovascular Disease in the Emilia-Romagna region (ALLEPRE) is a multicenter, randomized, controlled trial designed to compare the effects of a structured nurse-coordinated intensive intervention on long-term outcomes and risk profiles after an acute coronary syndrome with those of the standard of care. All of the patients randomized to the intervention group take part in 9 one-to-one sessions with an experienced nurse from the participating centers with the aim at promoting healthy lifestyles, reducing risk factors, and increasing adherence to medication over a mean period of 5 years. The primary clinical end point is the reduction in the risk of the 5-year occurrence of major adverse events (a composite of cardiovascular mortality, nonfatal reinfarction, and nonfatal stroke). The primary surrogate end point is the achievement of prespecified targets relating to classical risk factors, lifestyle modifications, and adherence to pharmacological therapy after 2 years of follow-up.
AB - The main objective of cardiovascular disease prevention is to reduce morbidity and mortality by promoting a healthy lifestyle, reducing risk factors, and improving adherence to medications. Secondary prevention after an acute coronary syndrome has proved to be effective in reducing new cardiovascular events, but its limited use in everyday clinical practice suggests that there is considerable room for improvement. The short-term results of evidence-based studies of nurse-coordinated secondary prevention programs have been positive, but there is a lack of long-term outcome data. The Alliance for the Secondary Prevention of Cardiovascular Disease in the Emilia-Romagna region (ALLEPRE) is a multicenter, randomized, controlled trial designed to compare the effects of a structured nurse-coordinated intensive intervention on long-term outcomes and risk profiles after an acute coronary syndrome with those of the standard of care. All of the patients randomized to the intervention group take part in 9 one-to-one sessions with an experienced nurse from the participating centers with the aim at promoting healthy lifestyles, reducing risk factors, and increasing adherence to medication over a mean period of 5 years. The primary clinical end point is the reduction in the risk of the 5-year occurrence of major adverse events (a composite of cardiovascular mortality, nonfatal reinfarction, and nonfatal stroke). The primary surrogate end point is the achievement of prespecified targets relating to classical risk factors, lifestyle modifications, and adherence to pharmacological therapy after 2 years of follow-up.
UR - http://www.scopus.com/inward/record.url?scp=85049337911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049337911&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2018.06.001
DO - 10.1016/j.ahj.2018.06.001
M3 - Article
AN - SCOPUS:85049337911
SN - 0002-8703
VL - 203
SP - 12
EP - 16
JO - American Heart Journal
JF - American Heart Journal
ER -